Introduction
Methods
Registers
Study population
Antipsychotics
Demographic data
Diagnostic profiles
Statistics
Results
Sedating | Less-sedating | ||||
---|---|---|---|---|---|
No | Yes | No | Yes | ||
Sex | |||||
Women; n (%) | 286 (52) | 268 (48) | 332 (60) | 222 (40) | |
Men; n (%) | 274 (46) | 323 (54) | 374 (63) | 223 (37) | |
Men vs women | |||||
RR (95% CI) | 1.11 (0.99–1.23) | 0.93 (0.80–1.07) | |||
p | 0.071 | 0.310 | |||
Year of birth | |||||
–1949; n (%) | 273 (51) | 266 (49) | 336 (62) | 203 (38) | |
1950–; n (%) | 287 (47) | 325 (53) | 370 (60) | 242 (40) | |
After vs before 1950 | |||||
RR (95% CI) | 1.09 (0.98–1.22) | 1.06 (0.92–1.23) | |||
p | 0.106 | 0.422 | |||
Severity of ID | |||||
Mild; n (%) | 329 (54) | 282 (46) | 378 (62) | 233 (38) | |
Moderate; n (%) | 118 (41) | 167 (59) | 166 (58) | 119 (42) | |
Severe/profound; n (%) | 113 (44) | 142 (56) | 162 (64) | 93 (36) | |
Moderate vs mild ID | |||||
RR (95% CI) | 1.13 (0.99–1.28) | 0.99 (0.83–1.17) | |||
p | 0.063 | 0.968 | |||
Severe/profound vs mild ID | |||||
RR (95% CI) |
1.17 (1.02–1.35)
| 0.91 (0.75–1.10) | |||
p |
0.029
| 0.325 | |||
Behavior impairment | |||||
Without; n (%) | 438 (55) | 352 (45) | 526 (67) | 264 (33) | |
With; n (%) | 122 (34) | 239 (66) | 180 (50) | 181 (50) | |
With vs without | |||||
RR (95% CI) |
1.34 (1.20–1.50)
|
1.42 (1.22–1.65)
| |||
p |
< 0.001
|
< 0.001
| |||
Living in special housing | |||||
Never | 107 (61) | 68 (39) | 118 (67) | 57 (33) | |
At least 1 year | 453 (46) | 523 (54) | 588 (60) | 388 (40) | |
At least 1 year vs never | |||||
RR (95% CI) |
1.25 (1.04–1.50)
| 1.16 (0.93–1.46) | |||
p |
0.019
| 0.192 |
Sedating | Less-sedating | |||
---|---|---|---|---|
RR (95% CI) |
p
| RR (95% CI) |
p
| |
A00–A09 intestinal infectious diseases | 0.68 (0.47–0.98) |
0.040
| 0.91 (0.63–1.32) | 0.625 |
A30–A49 other bacterial diseases | 0.99 (0.81–1.20) | 0.895 | 0.93 (0.74–1.17) | 0.538 |
B35–B49 mycoses | NI | 1.24 (0.87–1.75) | 0.230 | |
B95–B98 bacterial, viral, and other infectious agents | 1.05 (0.81–1.34) | 0.724 | 0.90 (0.67–1.21) | 0.476 |
C15–C26 malignant neoplasms of digestive organs | 1.01 (0.69–1.46) | 0.978 | 0.91 (0.56–1.47) | 0.688 |
C43–C44 melanoma and other malignant neoplasms of skin | 0.84 (0.65–1.09) | 0.191 | 1.06 (0.82–1.37) | 0.664 |
C50–C50 malignant neoplasm of breast | 1.13 (0.86–1.48) | 0.373 | 0.91 (0.63–1.31) | 0.602 |
D10–D36 benign neoplasms | 0.75 (0.53–1.05) | 0.095 | 0.79 (0.50–1.23) | 0.299 |
D37–D48 neoplasms of uncertain or unknown behaviour | 1.12 (0.80–1.56) | 0.521 | 0.99 (0.66–1.47) | 0.950 |
D50–D53 nutritional anaemias | 0.72 (0.54–0.97) |
0.030
| 1.02 (0.78–1.35) | 0.870 |
D60–D64 aplastic and other anaemias | 1.04 (0.85–1.27) | 0.706 | 0.94 (0.74–1.19) | 0.594 |
E00–E07 disorders of thyroid gland | 0.97 (0.79–1.18) | 0.740 | 0.94 (0.75–1.18) | 0.593 |
E10–E14 diabetes mellitus | 1.03 (0.91–1.17) | 0.629 | 1.25 (1.09–1.44) |
0.001
|
E65–E68 obesity and other hyperalimentation | 0.83 (0.59–1.17) | 0.288 | 0.66 (0.43–1.01) | 0.056 |
E70–E90 metabolic disorders | 1.19 (1.03–1.37) |
0.016
| 1.06 (0.89–1.27) | 0.494 |
F00–F09 organic, including symptomatic, mental disorders | 1.23 (1.07–1.41) |
0.003
| 1.55 (1.35–1.78) |
< 0.001
|
F10–F19 mental and behavioral disorders due to psychoactive substance use | 0.91 (0.73–1.14) | 0.423 | 0.77 (0.58–1.04) | 0.092 |
F20–F29 schizophrenia, schizotypal, and delusional disorders | 2.17 (1.99–2.36) |
< 0.001
| 1.81 (1.60–2.04) |
< 0.001
|
F30–F39 mood [affective] disorders | 1.48 (1.33–1.64) |
< 0.001
| 1.36 (1.20–1.54) |
< 0.001
|
F40–F48 neurotic, stress–related and somatoform disorders | 1.21 (1.07–1.37) |
0.002
| 1.30 (1.12–1.51) |
< 0.001
|
F50–F59 behavioral syndromes associated with physiological disturbances and physical factors | NI | 1.32 (0.81–2.15) | 0.259 | |
F60–F69 disorders of adult personality and behaviour | 1.17 (0.94–1.46) | 0.153 | 1.00 (0.73–1.38) | 0.976 |
F70–F79 mental retardation | 1.84 (1.70–1.99) |
< 0.001
| 1.68 (1.54–1.85) |
< 0.001
|
F80–F89 disorders of psychological development | 1.57 (1.44–1.71) |
< 0.001
| 1.34 (1.20–1.50) |
< 0.001
|
F90–F98 behavioral and emotional disorders with onset usually occurring in childhood and adolescence | 1.03 (0.80–1.32) | 0.823 | 1.53 (1.20–1.95) |
0.001
|
G20–G26 extrapyramidal and movement disorders | 1.02 0.78–1.33) | 0.895 | 1.00 (0.71–1.41) | 0.991 |
G40–G47 episodic and paroxysmal disorders | 0.90 (0.82–0.99) |
0.037
| 0.92 (0.82–1.03) | 0.141 |
G80–G83 cerebral palsy and other paralytic syndromes | 0.64 (0.52–0.80) |
< 0.001
| 0.85 (0.68–1.06) | 0.151 |
G90–G99 other disorders of the nervous system | 0.51 (0.29–0.91) |
0.022
| 0.89 (0.59–1.33) | 0.560 |
H15–H22 disorders of sclera, cornea, iris, and ciliary body | 0.82 (0.57–1.18) | 0.287 | 1.10 (0.79–1.54) | 0.571 |
H25–H28 disorders of lens | 0.86 (0.75–0.99) |
0.034
| 1.03 (0.89–1.19) | 0.684 |
H30–H36 disorders of choroid and retina | 1.00 (0.80–1.26) | 0.983 | 0.61 (0.47–0.80) |
< 0.001
|
H40–H42 glaucoma | 0.79 (0.61–1.03) | 0.080 | 1.04 (0.81–1.33) | 0.765 |
H49–H52 disorders of ocular muscles, binocular movement, accommodation, and refraction | 1.07 (0.82–1.40) | 0.617 | 1.06 (0.80–1.40) | 0.668 |
H53–H54 visual disturbances and blindness | 0.95 (0.70–1.28) | 0.732 | 0.72 (0.50–1.04) | 0.081 |
H90–H95 other disorders of ear | 1.06 (0.81–1.40) | 0.656 | 0.83 (0.55–1.25) | 0.375 |
I10–I15 hypertensive diseases | 0.63 (0.54–0.72) |
< 0.001
| 0.87 (0.75–1.01) | 0.072 |
I20–I25 ischaemic heart diseases | 1.06 (0.88–1.27) | 0.525 | 0.88 (0.70–1.12) | 0.308 |
I26–I28 pulmonary heart disease and diseases of pulmonary circulation | 1.25 (0.94–1.65) | 0.125 | 0.92 (0.59–1.43) | 0.706 |
I30–I52 other forms of heart disease | 0.90 (0.78–1.03) | 0.136 | 0.99 (0.84–1.17) | 0.938 |
I60–I69 cerebrovascular diseases | 1.09 (0.92–1.30) | 0.314 | 0.96 (0.78–1.18) | 0.682 |
I80–I89 diseases of veins, lymphatic vessels, and lymph nodes, not elsewhere classified | 0.85 (0.64–1.12) | 0.242 | NI | |
I95–I99 other and unspecified disorders of the circulatory system | 0.97 (0.69–1.39) | 0.888 | 1.34 (0.92–1.94) | 0.387 |
J00–J06 acute upper respiratory infections | 0.96 (0.76–1.22) | 0.739 | 1.12 (0.88–1.42) | 0.590 |
J09–J18 influenza and pneumonia | 1.10 (0.98–1.24) | 0.094 | 1.09 (0.95–1.24) | 0.793 |
J20–J22 other acute lower respiratory infections | 0.68 (0.49–0.95) |
0.025
| 1.28 (0.98–1.68) | 0.455 |
J30–J39 other diseases of upper respiratory tract | 0.95 (0.75–1.21) | 0.691 | 0.94 (0.70–1.27) | 0.981 |
J40–J47 chronic lower respiratory diseases | 1.27 (1.08–1.50) |
0.003
| 0.92 (0.73–1.16) | 0.931 |
J60–J70 lung diseases due to external agents | 0.96 (0.75–1.23) | 0.746 | 1.04 (0.78–1.39) | 0.983 |
J90–J94 other diseases of pleura | NI | 0.90 (0.57–1.43) | 0.504 | |
J95–J99 other diseases of the respiratory system | 1.25 (0.92–1.68) | 0.151 | 0.83 (0.54–1.27) | 0.429 |
K20–K31 diseases of oesophagus, stomach, and duodenum | 0.98 (0.83–1.16) | 0.803 | 0.95 (0.79–1.14) | 0.782 |
K40–K46 hernia | 0.87 (0.73–1.03) | 0.103 | 0.98 (0.81–1.17) | 0.959 |
K50–K52 noninfective enteritis and colitis | 0.65 (0.47–0.91) |
0.012
| 1.12 (0.83–1.50) | 0.705 |
K55–K63 other diseases of intestines | 1.07 (0.95–1.20) | 0.267 | 1.00 (0.86–1.15) | 0.393 |
K80–K87 disorders of gallbladder, biliary tract, and pancreas | 0.84 (0.66–1.06) | 0.146 | 1.01 (0.80–1.28) | 0.987 |
K90–K93 other diseases of the digestive system | 1.40 (1.17–1.67) |
< 0.001
| 1.00 (0.79–1.26) | 0.261 |
L00–L08 infections of the skin and subcutaneous tissue | 0.89 (0.61–1.29) | 0.539 | 1.14 (0.78–1.67) | 0.792 |
L40–L45 papulosquamous disorders | NI | 1.25 (0.72–2.14) | 0.664 | |
L80–L99 other disorders of the skin and subcutaneous tissue | 0.65 (0.46–0.92) |
0.016
| 0.95 (0.67–1.36) | 0.381 |
M05–M14 inflammatory polyarthropathies | 0.51 (0.30–0.87) |
0.014
| 1.01 (0.72–1.42) | 0.819 |
M15–M19 arthrosis | 0.98 (0.83–1.15) | 0.822 | 1.04 (0.86–1.25) | 0.228 |
M20–M25 other joint disorders | 0.90 (0.69–1.19) | 0.472 | 0.87 (0.64–1.19) | 0.570 |
M50–M54 other dorsopathies | 0.88 (0.61–1.25) | 0.464 | 1.00 (0.70–1.43) | 0.573 |
M70–M79 other soft tissue disorders | 0.93 (0.80–1.09) | 0.358 | 1.10 (0.93–1.31) | 0.124 |
M80–M85 disorders of bone density and structure | 1.17 (0.92–1.47) | 0.195 | 0.96 (0.73–1.27) | 0.387 |
N10–N16 renal tubulo-interstitial diseases | 0.74 (0.54–1.03) | 0.074 | 1.07 (0.79–1.46) | 0.590 |
N17–N19 renal failure | 0.99 (0.74–1.32) | 0.937 | 0.87 (0.63–1.20) | 0.793 |
N20–N23 urolithiasis | 0.78 (0.47–1.28) | 0.327 | 0.94 (0.57–1.56) | 0.455 |
N30–N39 other diseases of urinary system | 1.00 (0.89–1.12) | 0.940 | 0.92 (0.79–1.06) | 0.981 |
N40–N51 diseases of male genital organs | 0.71 (0.50–1.00) | 0.052 | 0.91 (0.64–1.27) | 0.931 |
N80–N98 noninflammatory disorders of female genital tract | 0.67 (0.43–1.05) | 0.082 | 0.88 (0.57–1.36) | 0.983 |
Q90–Q99 chromosomal abnormalities, not elsewhere classified | 0.59 (0.46–0.74) |
< 0.001
| 1.15 (0.96–1.38) | 0.504 |